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Abstract: Drosophila melanogaster (Drosophila) models of cancer are emerging as powerful tools to
investigate the basic mechanisms underlying tumour progression and identify novel therapeutics.
Rapid and inexpensive, it is possible to carry out genetic and drug screens at a far larger scale than
in vertebrate organisms. Such whole-organism-based drug screens permits assessment of drug
absorption and toxicity, reducing the possibility of false positives. Activating mutations in the Wnt
and Ras signalling pathways are common in many epithelial cancers, and when driven in the adult
Drosophila midgut, it induces aggressive intestinal tumour-like outgrowths that recapitulate many
aspects of human colorectal cancer (CRC). Here we have taken a Drosophila CRC model in which
tumourous cells are marked with both GFP and luciferase reporter genes, and developed novel
high-throughput assays for quantifying tumour burden. Leveraging these assays, we find that the
Drosophila CRC model responds rapidly to treatment with standard CRC-drugs, opening the door to
future rapid genetic and drug screens.
Keywords: Drosophila; colorectal cancer; high-throughput; drug screening
1. Introduction
Colorectal cancer (CRC) is the third most common cancer and the second most frequent
cause of cancer-related mortality [1]. With its high morbidity rate and incidence increasing
year by year, CRC has become a global health problem. Chemotherapy is currently regarded
as the standard treatment for patients with CRC, but it comes with many limitations, such
as systemic toxicity, low selectivity and insufficient concentrations in tumour tissues [2].
Combined with the ability of tumours to develop resistance to currently used therapy
regimes [3], there is a need not only for alternative therapies that will increase chemotherapy
treatment efficacy and reduce side effects, but also for new therapies that are less aggressive
and more effective than conventional ones [2,4].
The process of identifying new CRC therapies requires the use of systems that are cost-
effective, reliable and fast—preferably automated. Traditional approaches have employed
high-throughput screening for small molecules that is based primarily in 2D or 3D cell
culture, enzymatic assays or receptor binding assays. Such studies in 2D have relied on
the use of CRC cell lines such as Colo 205, SW480 or CR4, and assaying for effects on key
markers and genes required for growth, migration and invasion using a combination of
immunostaining, basic cell morphology, viability and proliferation assays [5–8]. 3D studies
in spheroids or organoids have provided the opportunity for more in-depth study of the
effects of treatments on physical tumour characteristics, with less reliance on biological
markers such as E-cadherin or Vimentin [9,10]. Increasingly complex manipulations of 3D
in vitro techniques have allowed the control of a variety of biochemical and biophysical
factors, while providing the capacity for real-time imaging with standard microscopy.
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While 2D and 3D cell-culture systems have evolved to enable more sophisticated high-
throughput therapeutic screenings, the ease of use and fast-turnaround times of such
in vitro studies comes at the cost of removing the rich biological environment found in vivo,
alongside a lack of targeted therapy delivery and limited physical outputs. Consequently,
the majority of positive hits identified through these types of in vitro screens, are later
found to be ineffective and/or toxic in subsequent validation experiments in whole-animal
models [11].
Drosophila melanogaster are emerging as a powerful alternative platform for high-
throughput drug screens. With a rapid life cycle and low maintenance costs, such whole-
organism-based drug screening permits the assessment of drug absorption, distribution,
metabolic stability and toxicity, reducing the possibilities of false positives. With nearly 75%
of human disease-causing genes believed to have a functional homologue in the fly [12],
Drosophila are increasingly used as screening platforms for drug discovery and translational
research [13,14]. There is a striking similarity between mammalian and Drosophila intestinal
tracts, which makes them particularly suited for modelling CRC [15]. While on a gross
anatomical level, the intestinal architecture differs between mammals and Drosophila,
they are composed of similar cell populations. The intestines in each are maintained by
proliferative cells that give rise to two types of post-mitotic cell types; absorptive cells
called enterocytes with a characteristic brush border and secretory cells. Therefore, the
Drosophila intestinal tract presents a ‘stripped down’ version of mammalian intestines that
retains essential features of the stem cell biology and niche, which are among the essential
features when modelling CRC.
A genetic powerhouse, the fly’s experimental tractability has identified a number of
cancer-initiating mutations and has led to the generation of a large number of Drosophila
models for different cancers [16,17]. Combined mutations in the WNT and EGFR pathways
are the most frequent initiating events of CRC [18], and we and others have previously
shown that it is possible to model CRC in Drosophila by inducing clonal activation of
the Wnt and Ras signalling pathways in the adult midgut [19,20]. Intestinal epithelial
ApcRas clones mutant for the negative regulators of the Wnt pathway, Apc and Apc2, and
overexpressing the oncogenic form of Ras, UAS-Rasv12, form tumour-like overgrowths.
We showed that these overgrowths reproduce many hallmarks of human CRC, including
increased proliferation, a block in cell polarity and differentiation, as well as disrupted
organ architecture. Furthermore, metabolic behavioural assays showed that these flies
suffer a progressive deterioration in intestinal homeostasis [19].
The behaviour of mutant clones generated in the adult Drosophila midgut is commonly
analysed by dissecting and imaging midguts, and quantifying parameters such as the
number of clones, the number of cells in a clone and the clonal area manually using
standard imaging analysis software [19,21,22]. As these methods are laborious, they cannot
be done on a rapid, large scale. Here, we have developed two approaches to make the
analysis of tumour burden in the Drosophila CRC model high-throughput, which could
be easily adapted to other cancer models. First, we have developed custom built macros
to be used in conjunction with Fiji, a widely available distribution of ImageJ for Life
Science, which allow for the automated analysis of the total area of the midgut taken up
with clones, as well as the average clone size. We demonstrate that clone size is the most
robust determinant of whether a clone is behaving as a tumour or not. Secondly, having
introduced a second reporter into the system, with clones now labelled with both GFP and
luciferase, we show that the overall tumour burden can be rapidly and cheaply assessed
by assaying whole fly lysates for luciferase. Finally, we show that after feeding drugs to
the flies in their food, these assays can be used to assess tumour burden accurately and
rapidly, and demonstrate a robust response of the Drosophila CRC model to conventionally
used CRC therapies. This study acts as a proof of principle to show that this model has the
capability to be used in a high-throughput manner for future small compounds screens, and
generates quantitative measurements of tumour characteristics that allow more in-depth
characterisation of the efficacies of compounds.
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2. Results
We have previously shown that, by means of the MARCM technique [23], we can
induce GFP-marked Apc-Ras clones in the intestinal stem cells of adult midguts. After
4 weeks, these clones form tumour-like overgrowths that share many similarities with
human CRC (Figure 1a and [19]), generating an excellent model in adult Drosophila for
CRC [19]. In order to be able to systematically quantify tumour growth, we recently
generated a new CRC model that expresses a UAS-luciferase transgene [24], in addition to
UAS-GFP, in the ApcRas background [25]. This model allows us to not only visualise cells
using GFP, but also to exploit the highly sensitive luciferase-based assay to test for tumour
burden, a process which is simple, quick to perform and provides rapid results. First, whole
flies are homogenised directly into a lysis buffer, then the luciferin substrate is added, and
finally the amount of luciferase activity is read using a luminometer (Figure 1b) [26]. As
luciferase readings can be performed using a microplate reader, this process can be scaled
up considerably, facilitating the analysis of many conditions in parallel.
As a first step towards setting up the conditions for screening whole flies for tumour
burden using luciferase, we first separately assayed the luciferase activity in homogenates
from 30 individual flies bearing ApcRas clones (Figure 1b). In agreement with the high
variability we described in this CRC model [19], we observed a high variability in the
luciferase readings between each fly, and thus used these measurements to determine the
average luciferase activity in a fly with ApcRas clones (Figure 1c). We next assayed the
luciferase activity in homogenates taken from pairs of flies, groups of 5 flies, or groups
of 10 (Figure 1c). We found that increasing the number of flies to be processed together,
not only reduces the variability in the luciferase readings, but leads to an almost identical
average readout for luciferase activity. Taken together, this suggests that a rapid assay
where 3 groups of 10 homogenised flies are put together, should give as reliable results as
30 individual assays. Using these conditions, we compared control flies bearing wildtype
clones with flies bearing ApcRas clones, and found that while they gave comparable
luciferase readings at 2 weeks, at 3 weeks their luciferase readings were significantly higher,
correlating with our previous observations of the timing of tumour development in this
model (Figure 1d compare with [19]).
We next sought to characterise in more detail how the whole fly luciferase readings
relate to the behaviour of GFP positive clones of cells within the gut. As well as providing a
more in-depth analysis of cell behaviour in different conditions, we reasoned that this could
be used as a secondary screen to validate hits from a luciferase screen. This process, which
we established when we developed and characterised the ApcRas model [19], involves
dissecting guts from mated females at 2 and 3 weeks after clones have been induced,
fixing and staining for GFP to visualise the clones, and phalloidin, which labels F-Actin
and shows the morphology of the midgut. As shown previously, control clones labelled
just with GFP and luciferase, form small clusters dispersed throughout the gut, that do
not appear to increase much in size (Figure 2a). In contrast, ApcRas clones disappear
over time, with the few that survive forming tumour-like overgrowths (Figures 1a and 2a
and [19]). Until recently, we quantified tumour burden by imaging each midgut, stitching
the images together manually (midguts can be up to 6mm long [27,28]), and then used
standard functions on Fiji to outline and calculate the area of each clone. While this method
provides highly accurate parameters to describe the behaviour of clones, it is extremely
laborious and can also introduce user bias.
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Figure 1. Assessing tumour burden by assaying for luciferase activity in whole flies. (a) Adult midguts dissected either
1 week (left), or 4 weeks after clone induction (right), stained for GFP (green) and phalloidin (red). By 4 weeks ApcRas
clones form large tumours in the anterior region of the midgut. (b) Schematic showing how luciferase assays are performed.
Flies are homogenised in a passive lysis buffer, which is then pipetted into a 96-well plate. Luciferin is added and the
resultant light is registered and processed via a plate-reader. (c) Luciferase assays performed on 30 flies individually, in
pairs, as groups of 5 and in groups of 10, respectively. (d) Luciferase assays performed on 3 batches of 10 control flies with
wildtype clones, or of flies bearing ApcRas clones. Graphs show violin plots with the median (solid line) and upper and
lower quartiles (dashed lines). Statistical analysis (c) is one-way ANOVA and (d) a Kruskall–Wallis test **** p ≤ 0.0001;
*** p ≤ 0.001; ns = non-significant. Scale bars = 500 µm.
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Figure 2. Tumour burden can be analysed automatedly across the entire midgut. (a,b) dissected adult midguts are stained
for GFP (green) and phalloidin (red). (a) GFP labelled clones 2 and 3 weeks after clone induction in Control and ApcRas
conditions. (b,b’) GFP positive areas across whole guts can be accurately selected using custom automated scripts. Blown-up
image sections are outlined by dashed white-lines. (c,d) Quantifications of the GFP% coverage of the anterior-portion of the
midgut (c) and GFP% coverage of the entire midgut (d) of control, and ApcRas clones at 2 and 3 weeks, n = 10. Graphs show
violin plots with the median (solid line) and upper and lower quartiles (dashed lines). Statistical analysis is Kruskall–Wallis
test. ** p ≤ 0.01; ns = non-significant. Scale bars = 500 µm (whole guts) and 50 µm (close-ups in b).
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Moving towards a more rapid system for clonal analysis across entire midguts, we
started to acquire tile-scans using a laser scanning microscope and image-stitching software,
which enables the automated acquisition of a single continuous image of the entire organ.
We have developed new tools for the analysis and extraction of reliable quantitative data
from these tile scans. We have made these custom scripts publicly available (see Section 4
for details on how to download and use them). They are for use with ImageJ, an open-
source imaging processing and analysis platform, and allow the automated and accurate
identification of GFP-positive areas along the entire midgut in seconds, as well as the
quantification of various parameters such as area of each individual clone, or sum of the
areas of all clones within a midgut (Figure 2b–d). They also provide an option for a variable
threshold which enables images of a range of qualities and microscopes to be analysed in a
similar manner, allowing comparisons to be made across a variety of equipment.
As ApcRas clones are confined to the anterior portion of the midgut by 3 weeks after
clone induction, we previously quantified tumour burden by calculating the % of the
anterior portion of the midgut taken up by GFP positive clones [19]. We therefore tested
our custom macros by measuring the total clone area of wild type or ApcRas clones within
the anterior portion of the midgut, along with the area of the anterior portion of the midgut
itself, enabling the percentage area of the anterior midgut covered by clones to be calculated
automatedly. While this requires manual selection of the anterior portion of the midgut,
the use of thresholding and the automated quantification of GFP positive area removes
potential user bias and, with proper thresholding, selects GFP positive clones only in the
current Z-plane.
While the percentage coverage of the anterior portion of the midgut presents a reliable
metric for analysing changes to the tumour burden in the ApcRas model, this may not
extend to other models where clones are more evenly distributed throughout the midgut.
We therefore also developed a macro to measure the entire midgut area, enabling the
calculation of the percentage of the entire midgut covered by clones. In order to further
increase the high throughput capabilities of this model of CRC, we also developed a macro
that quantified the GFP positive area, along with the whole area of objects in the red
channel, of consecutive images. This allows extremely large batches of dissected guts,
or even whole experimental conditions, to be processed in minutes. Interestingly, while
the calculation of the GFP positive area in the anterior region of midguts is significantly
higher in the ApcRas conditions than in controls (Figure 2d), the percent of the entire
midgut covered by GFP positive clones shows no significant difference (Figure 2c). This
suggests that while the percentage coverage of the anterior portion of the midgut may be a
good metric for analysing the tumour burden in the ApcRas model versus wildtype, the
percentage coverage of the whole midgut is not. Therefore, for a high-throughput screen for
drugs altering the tumour burden in the ApcRas model, which may affect the distribution
of clones across the midgut, or for measurements in any condition where clones are not
restricted to one portion of the midgut, other parameters may be more informative.
This raises the question as to what quantifiable parameters may determine the differ-
ence between a wildtype control clone, a clone that has over-proliferated but not formed a
tumour, and a tumour-like clone where cells have lost polarity and are undifferentiated.
In previous work, we have shown that the overexpression of Snail in the intestinal stem
cells leads to the over-proliferation of cells, but clones do not form tumours [25]. We
therefore decided to look in detail at the cell morphology, and distribution of either control
clones, clones over expressing Snail or ApcRas clones (Figure 3a–f), to identify quantifiable
parameters that could be leveraged to distinguish what kind of clone has formed. We
found that the tissue architecture, cell organisation and nuclei size are distinct between
control clones (Figure 3a,b), Snail clones (Figure 3c,d) and ApcRas clones (Figure 3e,f).
The adult Drosophila intestinal tract shows high levels of cellular heterogeneity, as the
epithelium is composed of a range of cell types, as well as cells of varying ages, as the
epithelium undergoes continual cell turnover. Regardless of this high heterogeneity, the
cell morphology and general tissue architecture in control clones and Snail clones is rela-
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tively consistent and well-organised (Figure 3a–d), while ApcRas clones exhibit poor cell
organisation, large variation in cell morphology and shape, increased nuclei density within
clones and a huge range of nuclei sizes—characteristics displayed in mammalian epithelial
tumours (Figure 3e,f). A key difference between clones of cells which have overproliferated
versus tumour-like clones is an increase in the maximal nuclear size; the maximal nuclear
size in control and Snail clones is 420 µm2, whereas nuclei in ApcRas are on average bigger
and can be as large as 980 µm2 in diameter. While nuclei in ApcRas clones are more
packed than in controls (Figure 3 compare e with a), this is also seen in over proliferating
conditions (Figure 3c). In contrast, while control and Snail clones are always found within
a single layer (Figure 3b,d), ApcRas clones are multi-layered and protrude into the lumen
of the midgut (Figure 3f). However, assessing whether clones have become tumour-like by
their maximum nuclear diameter and extent of which they have become multi-layered or
protrude into the lumen is very time consuming, as the midgut is a very thick tissue and
it requires taking many z-slices in high resolution. Combining this with the need for tile
scans to capture the entire length of the midgut, this suggests that while these parameters
can be used to assess a few samples, it would not be practical to use them as outputs for a
high-throughput screen.
The formation of these large multi-layered tumours, suggested that tumour-like
clones could be distinguished from controls and over-proliferating cells by size. Therefore,
automated scripts were developed to measure clone area of all clones along the entire
midgut. These showed that the large clones over 7800 µm2, likely formed by the merging
of multiple clones, are only seen in ApcRas conditions, and never seen in control or in
Snail clones (Figure 3g). This occurs without any significant changes in the overall gut area
(Figure 3h). Importantly, comparable results were seen whether these were analysed from
a tile scan across 3 z-planes of the midgut, or across a z-stack through the entire midgut.
Taken together, these results suggest that the clone area is a robust and reliable readout for
the presence of tumour-like clones in the midgut and can be assayed and compared using
just 3 z-planes.
Once the conditions for screening ApcRas flies for tumour burden had been estab-
lished, we next wanted to test whether the Drosophila CRC model responds to drugs
currently used to treat human tumours. We decided to test two drugs: Oxaliplatin (Oxal)
and 5-Fluoro-5′-Deoxyuridine (5-Fluoro), two chemotherapy drugs that are standard treat-
ments for patients with CRC [29]. Oxal is a platinum-based DNA crosslinking agent [30],
whereas 5-Fluoro is a Fluorouracil derivative which acts as an antimetabolite by blocking
synthesis of thymidine [31], and both act to block cell division. We reasoned that their
efficacy in treating human CRC suggested that they would be good candidates to test
our model.
Flies bearing ApcRas clones were induced in adult midguts and allowed to develop
for 1 week. The flies were then transferred to new vials containing either food alone
(Untreated), food mixed with Oxal or 5-Fluoro or with the additional control of Dimethyl
sulfoxide (DMSO) alone, as this was used to dilute the drugs before adding to the food.
The drugs were diluted to a final concentration of 100 µM within the food. Flies were left
on the food with drugs or control food for 2 weeks, and then assayed for tumour burden
by luciferase assays on whole flies (Figure 4a). These revealed that treatment with either
Oxal or 5-Fluoro leads to a large reduction in the overall tumour burden when compared to
untreated flies, or flies fed with DMSO alone (Figure 4b). This demonstrates that Drosophila
CRC flies show a rapid and robust response to treatment with standard human CRC
therapeutics. Moreover, this suggests firstly that the Drosophila CRC model may be a viable
screening platform for drugs for treating human CRC. Secondly, as luciferase assays can
be performed on whole fly homogenates in 96-well plates, this approach is scalable to
high-throughput.
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Figure 3. Distinguishing between control, over-proliferating and tumour-like clones. (a–f) representative clones from
control, UAS-Sna and ApcRas midguts stained for GFP (green) ((a’,c’,e’) show GFP alone) and Dapi ((a,a”,c,c”,e,e”) white) or
phalloidin ((b,d,f) red). (a,c,e) longitudinal sections and (b,d,f) orthogonal views of control (a,b) UAS-Sna (c,d) and ApcRas
(e,f) midguts. While the lumen of midguts containing either control or over-proliferating clones consist of a single-layered
epithelium and are continuous and clear (b,d), there is multi-layering in the epithelium of midguts with ApcRas clones,
which often have luminal-blockages and a discontinued lumen (f). (g,h) Graphs showing scatter plots with min and max
((g) solid horizontal lines) and violin plots with the median ((h) solid line) and upper and lower quartiles ((h) dashed lines).
(g) Quantifications of the area of clones found in midguts with either Control, UAS-Sna or ApcRas clones. Clones of over
7800 µm2 (dashed line delineates this threshold) are only found in the ApcRas model. Statistics were performed on the
number of clones found over the threshold. (h) The average area of the whole midgut is not significantly altered in any of
the conditions. Statistical analysis was a Kruskall–Wallis test. **** p ≤ 0.0001; ns = non-significant. Scale bars = 20 µm.
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We also followed the % survival of both ApcRas and control flies over the 3 week
period as another potential readout for the screen. However, we found only subtle affects
with each genotype and treatment: DMSO slightly lowers the survival rate of control flies,
and this is partially rescued with feeding on DMSO + Oxal or DMSO+5′Fluoro (Figure 4c);
DMSO also lowers the survival rate of ApcRas flies, and this is also partially rescued by
treatment with either Oxal or 5-Fluor, with Oxal bringing the % survival almost as high
as control flies fed on DMSO (Figure 4c). These small changes in survival rates over the
3-week period fits with previous data showing that ApcRas flies display a 50% survival
rate at 4 weeks after clone induction [19], suggesting that flies would need to be monitored
for longer than 3 weeks for any effects on survival to be seen. For this to be a robust readout
of the screen, it would need to be performed on more flies, over an even longer time course.
Taken together, this suggests that luciferase readings on whole flies presents a far more
rapid assay to screen for putative CRC treatments in flies.
We next sought to characterise in more detail how flies bearing ApcRas clones respond
to treatment with Oxal or 5-Fluoro and determine if their effects are specific to the tumour-
like ApcRas clones by comparing with control clones. To do this, we studied the behaviour
of both control and ApcRas clones in the midguts of flies fed with the different conditions,
by dissecting out their midguts after 3 weeks and staining them for GFP and phalloidin,
which labels F-actin and can be used to visualise the outline and overall organisation of
the midgut. We found that the midgut morphology and size was not affected and the
distribution and size of control clones were the same in all conditions (Figure 4d). In
contrast, while the midguts of ApcRas flies raised on untreated and DMSO food had large
tumour-like clones in the anterior region of the midguts, the clones in flies fed with Oxal
and 5-Fluoro were greatly reduced (Figure 4d). Thus, the reduction in clone size and
distribution appears to be specific to clones with tumour-like properties.
We quantified the behaviour of clones in the different conditions by dissecting, fixing
and immunostaining the midguts from these flies, and then analysing the clonal area as
a percentage of the anterior region of the midgut or of the whole midgut. Both analyses
revealed a reduction in coverage by GFP positive clones by around 50% when the flies
were treated with either Oxal or 5-Fluoro (Figure 4d,e). The fact that no reduction was seen
in the coverage by control clones (Figure 4e,f) suggests that treatment with the standard
chemotherapies used to treat human CRC specifically target the tumour-like ApcRas clones,
without causing any significant changes to normal wildtype cells.
To look in more detail at the behaviour of ApcRas clones upon treatment with Oxal or
5-Fluoro, we next used our automated scripts to analyse the area of all the clones across
the entire midgut in ApcRas conditions on each treatment. We found that many very large
clones over 7800 µm2 in size are found in both untreated ApcRas flies, or ApcRas flies
treated with DMSO alone. Strikingly, after ApcRas flies have been treated with either
Oxal or 5-Fluoro, almost no flies are found to contain clones over the 7800 µm2 threshold,
further confirming the efficacy of these treatments (Figure 5a). In support of this, we
found that other tumour-like characteristics of ApcRas clones are reduced (Figure 5b–i); the
maximum nuclear size within a clone was reduced from 986 µm2 to ~680 µm2, and while
cross sections of midguts showed that there was still some multilayering of cells within
ApcRas clones, they never caused the complete luminal blockages seen when these tumour-
like clones were left to grow untreated (Figure 5 compare Figure 5g,i with Figure 5c,e).
Taken together, these results suggest that while treatment with CRC therapeutics did not
completely abrogate tumour growth, the tumour burden was dramatically reduced, and
this was accompanied by a reduction in the appearance of clones bulging into the lumen of
the gut.
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Figure 4. Treatment with Oxal or 5-Fluoro decreases primary tumour burden. (a) Schematic of the drug treatment regimen.
Flies are heat-shocked (day ‘0’) and left on untreated food for 1 week, followed by transfer to a food containing drugs for
2 weeks. The flies are then sacrificed and assayed for tumour burden. (b) Luciferase assays performed on 3 batches of
10 ApcRas flies 3 weeks after clone induction, treated with food either without anything added (Untreated), with DMSO
alone (DMSO) or with drugs added that were dissolved in DMSO (Oxal) or (5-Fluoro). (c) Survival curves for control (solid
lines) and ApcRas (dotted lines) flies fed on untreated food (blue) or on food with DMSO alone (red), Oxal (orange) or
5-Fluoro (grey) added with DMSO. The survival of the flies was monitored over the 21 days of each experiment. Numbers
were the same for each genotype: untreated n = 80, DMSO n = 78, Oxal n =80, 5-Fluoro n =82. (d) Dissected midguts from
either control or ApcRas flies stained for GFP (green) and phalloidin (red). (e,f) Quantifications of the GFP% coverage of the
entire midgut (e) or of the just the anterior-portion of the midgut (f) of control (Con) or ApcRas (AR) clones at 3 weeks on
the different drug regimens, n = 10 for each condition. Graphs show violin plots with the median (solid line) and upper
and lower quartiles (dashed lines). Statistical analysis is Kruskall–Wallis test. ** p ≤ 0.01; * p ≤ 0.05; ns = non-significant.
Scale bars = 500 µm.




Figure 5. Treatment with either Oxal or 5′-Fluoro results in a decrease in tumour-like clones in the ApcRas model.
(a) Quantifications of the area of clones found in midguts of ApcRas clones on different drug regimens. Data is displayed
as a scatter plot with min and max ((a) solid horizontal lines) and a dashed line delineating 7800 µm2, clones larger than
which are normally only found in tumourigenic conditions. While many clones over 7800 µm2 are found in ApcRas flies in
untreated or DMSO conditions, when treated with Oxal or 5-Fluoro clones larger than 7800 µm2 are rarely found. Statistics
were performed on the number of clones found over the threshold. (b–i) Representative ApcRas clones in flies fed with
untreated food (b,c) food with DMSO (d,e) with Oxal (f,g) or with 5′-Fluoro (h,i). (b,d,f,h) are longitudinal sections and
(c,e,g,i) orthogonal views. (b’,d’,f’,h’) show GFP alone; (b”,d”,f”,h”) show DAPI alone. (c–i) ApcRas flies treated with Oxal
or 5-Fluoro show reduced formation of tumour-like clones, multilayering and luminal blockages. Statistical analysis is
Kruskall–Wallis test. **** p ≤ 0.0001; ns = non-significant. Scale bars = 50.
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3. Discussion
To date, current drug discovery pipelines have had very limited success in delivering
drugs identified in vitro, into the clinic for anti-cancer therapy [32,33]. With research in
Drosophila providing the first glimpse into the mechanism of action of many human cancer-
related proteins, it is now emerging as an important new platform for anti-cancer drug
discovery [34]. Rapid and cost effective, its key advantage over classic in vitro screens is the
identification of drugs that can specifically target tumours in vivo. This permits assessment
of drug absorption and toxicity, reducing the possibility of false positives, as well as
assaying drug effects on tumour cells which are maintaining key interactions occurring
during normal disease progression, such as with the tumour microenvironment. Moreover,
the fast genetic manipulation of Drosophila presents the possibility to personalise transgenic
cancer models, in which mutations are directly based on individual tumour genome profiles.
Such models have been used to analyse a collection of drugs and assess the mechanisms
of emerging drug resistance [35]. Remarkably, the generation of a personalised model of
a treatment-resistant metastatic KRAS-mutant colorectal cancer in Drosophila larvae has
led to the identification of a drug combination, trametinib and zoledronate, that has been
used as a treatment for the patient [36], highlighting the potential of Drosophila as a model
for personalised medicine. Here, we have developed sensitive high-throughput assays, to
rapidly and accurately assay for tumour burden in a Drosophila model for benign CRC, that
has previously been shown to recapitulate many hallmarks of the human disease [19]. We
show that it responds to treatment with standard chemotherapies used to treat human CRC,
suggesting that compounds identified in future screens in this model may be transferable
to humans.
Introducing two reporters into the system, firefly luciferase and GFP, makes the
Drosophila ApcRas model amenable to two distinct methods of screening. The first, as-
saying for luciferase activity in whole flies, enables high-throughput batch processing of
whole flies, to identify overall changes in tumour burden. The second method relies on the
visualisation and quantification of the GFP reporter. It not only enables the verification
of changes detected by luciferase assays, but gives a more in-depth analysis of individual
clone behaviour in a semi high-throughput capacity. Excitingly, this suggests that screening
batches of flies with luciferase assays could work as a primary screen, and positive candi-
dates could be followed up in a second screen where midguts are dissected and analysed
using our high-throughput scripts.
Here we show that a Drosophila model for benign CRC rapidly responds to treatment
with standard chemotherapy drugs, and that the response can reliably and reproducibly be
assessed in a high-throughput manner. This process is highly scalable to the screening of
thousands of flies, opening the door for drug screens to test either single compounds, or
multiple compounds in combination. As Drosophila are highly genetically tractable, once a
drug or drug combination has been identified, this could later be combined with a genetic
screen to identify the drugs in vivo targets. Given the current need for new therapies for
CRC that have less side effects and are more effective than conventional ones, the ApcRas




MARCM clones were generated by a 1-h heat shock at 37 ◦C of 2–5-day-old females
and were marked by the progenitor cell marker escargot (esg) Gal4 line driving the expres-
sion of UAS GFP.
4.2. Genotypes
yw hsp70-flp; esg-Gal4, UAS-GFP, UAS-RasV12/CyO; UAS-Luciferase FRT82B, Gal80/TM6b
flies were crossed with yw hsp70-flp; Sp/CyO; FRT82B, Apc2N175KApcQ8/TM6b flies to
generate ApcRas clones. yw hsp70-flp; esg-Gal4, UAS-GFP/CyO; UAS-Luciferase FRT82B
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Gal80/TM6b flies were crossed with yw hsp70-flp; UAS-Sna/CyO; FRT82B/TM6b flies to
generate Snail clones and to yw hsp70-flp; If/CyO; FRT82B/TM6b flies to generate GFP
clones. Apc2N175K is a loss-of-function allele, ApcQ8 is a null allele, UAS-RasV12 is a gain-
of-function transgene, and UAS-Sna is a wildtype transgene. All balancers (Cyo and TM6b)
were compound balancers. UAS-Sna was a gift from Justin Kumar. All other stocks were
obtained from Bloomington Stock Centre.
4.3. Drug Administration
5-Fluoro-5′-Deoxyuridine (Sigma-Aldrich, Merck Life Science UK Limited, Dorset,
UK; F8791) and Oxaliplatin (Sigma-Aldrich, Merck Life Science UK Limited, Dorset, UK;
09512) were dissolved in DMSO and added to molten fly food—ensuring temperature of
molten fly flood did not exceed the thermostabilities of compounds. DMSO alone was
added to molten fly food as a control. Drugs were diluted to a concentration of 100 µM,
as has been shown to be effective in other studies where compounds are fed to Drosophila
cancer models [37].
4.4. Staining and Antibodies
Adult female flies were dissected in phosphate-buffered saline (PBS). All whole diges-
tive tract was removed and fixed in PBS and 4% electron microscopic-grade paraformalde-
hyde (Polysciences, Warrington, PA, USA) for 35 min. Samples were rinsed 3 times with
PBS, 4% bovine serum albumin (BSA), and 0.1% Triton X-100 (PBT-BSA) and incubated
with the primary antibody overnight at 4 ◦C and with the secondary antibody for 2 h at
room temperature. Finally, the samples were rinsed 3 times with PBT-BSA and mounted in
DAPI-containing Vectashield (Vector Laboratories, Burlingame, CA, USA). All the steps
were performed without mechanical agitation. Primary antibodies were goat anti-GFP
(1:500; Abcam, Cambridge, UK, ab6673) and rabbit anti-Laminin (1:500, Abcam, Cambridge,
UK, ab47651). Secondary antibodies were from Invitrogen (Carlsbad, CA, USA). Phalloidin
(Sigma-Aldrich, Merck Life Science UK Limited, Dorset, UK; P1951) was used at 5µg/mL.
Confocal image were acquired with a Zeiss LSM 880. Images were analysed with the Fiji
software (National Institutes of Health (NIH) Bethesda, MD) and assembled into figures
using Fiji version 1.0, Adobe Photoshop CC 2017 software (Adobe, San Jose, CA, USA),
and Microsoft Powerpoint.
4.5. Luciferase Assays
Luciferase assays were performed using the Dual-Luciferase(R) Reporter Assay Sys-
tem. Flies were squashed using a 200 µL pipette tip into a Passive Lysis buffer and samples
loaded into 96-well plates. Luciferin substrate (LARII) added and bioluminescence read on
a Varioskan plate reader.
4.6. Image Analysis
The macros presented in this study are for use with ImageJ (https://imagej.net/Fiji/
Downloads (accessed on 1 July 2020)). ImageJ is an open-source imaging processing and
analysis platform, originally developed at the National Institutes of Health (Bethesda, MD,
USA). We recommend using ImageJ Fiji distribution. In principle Fiji should run on all
major computer platforms, including Microsoft Windows, Mac OS and Linus.
The macros are briefly described below and can be found here: https://github.com/
Jadams94/AutomatedGutQuant (accessed on 1 May 2021).
BatchGutGFP%CoverageMacro: This macro measures the overall area of GFP positive
pixels and the overall area of an object in the red channel of an RGB image. These area
measurements can then be used to calculate the overall GFP% coverage of an object within
an image.
BatchGutGFP%CoverageMacro: This macro measures the overall area of GFP positive
pixels and the overall area of an object in the red channel of consecutive RGB images within
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a specified folder. These area measurements can then be used to calculate the overall GFP%
coverage of an object within each image.
GFPMaskAreaQuantMacro: This macro measures the area of each individual GFP
positive mask of an RGB image.
These macros should be downloaded onto your computer and dragged and dropped
to the Fiji bar to be used. The purpose and directions for use of each macro are incorporated
within each file.
4.7. Statistical Analysis
All statistical analyses and graphical representation were carried out using GraphPad
Prism 8 (GraphPad Software, San Diego, CA, USA).
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